Journal
EUROPEAN THYROID JOURNAL
Volume 11, Issue 1, Pages -Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ETJ-21-0046
Keywords
differentiated thyroid cancer; radioiodine; treatment; indications
Categories
Ask authors/readers for more resources
The use of post-operative RAI treatment for DTC should be based on patient's risk stratification. While the benefits of radioiodine are clear for high-risk patients, its use in intermediate-risk and some low-risk patients remains controversial. New guidelines have been developed, taking into consideration retrospective data and the results of prospective randomized trials, to address questions regarding patient selection, RAI activity, and pre-treatment patient preparation.
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients' risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available